- Press Release -

Award-winning consulting firm Fact.MR’s report on the global human umbilical vein endothelial cells (HUVEC) market forecasts a healthy growth trajectory for the 2021-2031 forecast period. According to the study, rapid advancements in biotechnology and genetic engineering are opening up new growth avenues for advanced disease treatment, particularly across areas such as oncology.

As per data published by GLOBOCAN, the global cancer burden rose to 19.3 million cases, while associated fatalities increased to 10 million by 2020. Amongst all the cancers, breast cancer accounts for nearly a quarter of the total cases diagnosed every year. Hence, healthcare providers are incorporating highly advanced therapeutic approaches, thereby widening the growth prospects for human umbilical vein endothelial cells.

Manufacturers are directing the bulk of their investments across key regions such as China, India, and other countries in the Asia Pacific. Over the years, these countries have witnessed an unprecedented expansion of their existing healthcare infrastructure. This is majorly attributed to the presence of a huge population base, necessitating the delivery of advanced healthcare for various chronic and infectious diseases.

Key Takeaways from Market Study

• By type, pooled donor-derived HUVECs are expected to experience elevated sales through 2031
• Oncology to emerge as a highly promising application area for HUVEC-based treatment
• The U.S. to generate multiple revenue streams for the market, across CVD treatment, oncology, and angiogenesis
• Extensive development of biotechnology and cell culture studies driving demand across India

“Rapid advancements in healthcare are prompting developments across key therapeutic areas, providing enough room for the proliferation of HUVEC-based therapeutics,” remarks a Fact.MR analyst.

Competitive Landscape

Prominent HUVEC providers as profiled by Fact.MR include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc. Due to the presence of such a handful of service providers, the market appears highly consolidated.

• In May 2021, Merck & Co. announced 40 abstracts, seven oral presentations, and seven poster discussions from company and investigator sponsored studies and external collaborations for its oncology treatment furtherance, an initiative that will likely provide tailwinds to its HUVEC portfolio.
• In January 2021, PromoCell received the EXCiPACTTM certification scheme for pharmaceutical excipients to Good Manufacturing Practice (GMP) standards, which implied that the company can provide tailor-made cell culture media and reagents based on each client’s end-user requirements.

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the human umbilical vein endothelial cells market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of type (single donors and pooled donors) and application (wound healing, angiogenesis, tissue engineering, inflammation, oncology, and others), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

Fact.MR’s Domain Knowledge in Healthcare

Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.

For more information, refer to our market research report or contact the PR author.

Shambhu Nath Jha

Fact.MR

Sr. Consultant – Healthcare

E-mail: shambhu@factmr.com